Every 2.1 seconds, someone in the world suffers a stroke.  For those who are lucky enough to survive, overcoming paralysis can take months or even years of intense therapy.  

Too often, patients are treated in facilities that do not offer the latest advances in stroke rehabilitation technology. Then, they are often sent home with no effective home program and without the tools and resources they need to recover. Most at home stroke rehabilitation technology is overpriced, ineffective, or too complicated for home use.

All along the way, doctors routinely misinform stroke patients about the potential for additional recovery. Many patients are told that they have reached a recovery “plateau” and additional progress is no longer possible.

Without help, patients experience worsening paralysis, decreased range-of-motion, increased pain and depression, and a deteriorating quality-of-life. 

Making matters worse, even in developed countries like the U.S., insurance rarely covers the cost of long-term therapy or innovative rehabilitation products. 

The latest research demonstrates that it doesn’t have to be this way. Today, we now know that recovery can continue for many years, even decades, but only if patients get the help they need. 

Our lifetime net revenue is at over $44 million and we’ve seen tremendous growth to-date across our B2B and B2C sectors:

• A distributor network spanning 6 continents and over 40 countries

• 17 Patents: our innovative product designs have been awarded 17 different patents by the US Patent Office

• FDA clearance: our products has already satisfied FDA pre-marketing requirements or are regulated as class I devices, which are exempt from premarket requirements

• Global adoption: Our products have been used by an estimated 800,000 patients in more than 4,000 hospitals around the world. 

Additionally, our products are recommended by the 10 top rehabilitation hospitals in the US (as ranked by US News and World Report). Our products and treatment approaches have now been featured in 20 different medical textbooks and publications, authored by the top neurologists and professors around the world. Saebo products and programs are featured in numerous university curriculums around the world.

Our very first product, the SaeboFlex, was recently put on permanent display at the London Science Museum alongside other breakthrough medical technologies such as penicillin and the first MRI.

With over $44 million in net revenue to date, Saebo has a well-established multi-channel business model.

We sell products directly to the end-user through our D2C e-commerce platform. This platform leverages clinical expertise, producing educational content that generates over 250,000 website visits per month. This has paved the way for our significant digital footprint.

Another primary revenue stream is our B2B channel. We sell products directly to hospitals and treatment centers for use in the care of their patients. 

We also sell our products through various domestic and international healthcare providers and medical product distributors. This hybrid approach leverages a wide network of international distributors, who can then leverage their insurance networks and/or provider networks to navigate local compliance and logistics issues.

We have seen steady growth to-date across all of these channels:

• 90% compound annual growth rate (CAGR) for products sold to US patients through our ecommerce platform since 2017.

• 27% compound annual growth rate (CAGR) for direct-to-patient unit product sales between 2013 and 2018.

• 10% compound annual growth rate (CAGR) for equipment sold to hospitals between 2013 and 2018.

And our multi-channel approach is now delivering scalable, capital-efficient growth opportunities based on falling customer acquisition costs and increasing customer lifetime values. Our current cost-per-acquisition is around $45 and our estimated lifetime value is about $300 per customer and rising.

Saebo is a well-established leader in the neurorehabilitation market for a significant population of stroke survivors:

• Globally, there are over 15 million stroke survivors (source).
  
  
• The U.S. alone is home to over 6.4 million stroke survivors with another 800,000 new survivors every year (source).
  
  
• Between 2010 and 2050 the number of strokes in the U.S. is projected to double (source).
  
  
• By 2030, almost 4% of US adults will have had a stroke (source).
  
  
• Roughly 70% of stroke survivors are 65 or older; one of the fastest-growing demographics in the developed world (source).
  
  
• Stroke is the number one cause of long-term adult disability worldwide (source).
  
  
• The total direct annual stroke-related medical costs are projected to increase from $71 billion in 2012 to $183 billion by 2030 (source).

Consistent, long-term growth in the worldwide market for stroke rehabilitation products will be driven by a number of factors including:

• Increasing stroke incidence levels due to changing demographics and lifestyles (as people live longer, they are more likely to have a stroke at some point in their lives).
  
  
• Increasing stroke survival rates due to advances in acute medical care (growing number of survivors means more require post-stroke rehabilitation).
  
  
• Increasing demand for new technologies due to advances in neuroscience (new evidence on cortical plasticity is demonstrating that old approaches to treatment are no longer adequate)

And finally, with COVID-19, we have seen an increased incidence of stroke. Particularly with pandemic restrictions, there is an increased urgency and demand for effective in-home therapy.

With a combined 112 years of clinical experience and 49 years of management experience, the Saebo team is made up of exceptional leaders in business and medicine, poised to change the lives of patients around the world. 

To continue to provide life-changing solutions for those suffering from impaired mobility and function, Saebo aims to expand global partnerships and provide directly accessible devices for every patient who needs them.

We hope to follow our momentum with funding from StartEngine for new product development, lower-cost product sourcing, a sophisticated DTP digital marketing platform, and additional domestic and international distribution channels and partners. We hope you will join the charge to provide innovative, affordable, and positively impactful solutions so that no patient is ever left behind.

gif